Pharmaceutical

OptiNose (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.25 per share, before underwriting discounts. The offering consists of 2,500,000 shares being sold by Optinose and 2,500,000 shares being sold by certain selling stockholders, resulting in aggregate net proceeds of approximately …

OptiNose (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.25 per share, before underwriting discounts. The offering consists of 2,500,000 shares being sold by Optinose and 2,500,000 shares being sold by certain selling stockholders, resulting in aggregate net proceeds of approximately $52.3 million to Optinose and approximately $52.3 million to the selling stockholders, after deducting underwriting discounts and before offering expenses.

As quoted in the press release:

In addition, Optinose and the selling stockholders have granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 750,000 shares at the public offering price, less the underwriting discount. Optinose will not receive any proceeds from the sale of shares by the selling stockholders.

The offering is expected to close on or about June 11, 2018, subject to satisfaction of customary closing conditions. Registration statements relating to these securities were declared effective by the Securities and Exchange Commission on June 6, 2018.

Click here to read the full press release.

MARKETS

Markets
TSX20181.44-88.53
TSXV660.08-9.49
DOW33980.32-171.69
S&P 5004274.04-31.16
NASD12938.12-164.43
ASX7105.40+41.10

COMMODITIES

Commodities
Gold1761.65-13.82
Silver19.79-0.34
Copper3.60-0.03
Palladium2142.76-2.25
Platinum929.03-4.97
Oil87.29+0.76
Heating Oil3.55+0.11
Natural Gas9.18-0.15

DOWNLOAD FREE REPORTS

×